Recent developments in ghrelin receptor (GHS-R1a) agonists and antagonists

Bibliography

• KOJIMA M, HOSODA H, DATE Y et al: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature (1999) 402:656–660.
   PubMed Web of Science ®Google Scholar
• ••First report on the isolation andcharacterisation of ghrelin.
   Google Scholar
• HOSODA H, KOJIMA M, MATSUO H, KANGAWA K: Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem. Biophys. Res. Commun. (2000) 279:909–913.
   PubMed Web of Science ®Google Scholar
• HOSODA H, KOJIMA M, MATSUO H et al.: Purification and characterization of rat des-G1n14-ghrelin, a second endogenous ligand for the growth hormone secretagogue receptor. Biol. Chem. (2000) 275:21995–22000.
   Web of Science ®Google Scholar
• ARIYASU H, TAKAYA K, TAGAMI T et al.: Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. I Clin. Endocrinol Met. (2001) 86:4753–4758.
   PubMed Web of Science ®Google Scholar
• DATE Y, KOJIMA M, HOSODA H et al.: Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology (2000) 141:4255–4261.
   PubMed Web of Science ®Google Scholar
• MORI K, YOSHIMOTO A, TAKAYA K et al.: Kidney produces a novel acylated peptide, ghrelin. FEBS Lett. (2000) 486:213–216.
   PubMed Web of Science ®Google Scholar
• HOWARD AD, FEIGHNER SD, CULLY DF et al.: A receptor in pituitary and hypothalamus that functions in growth hormone release. Sdence (1996) 273:974–977.
   Google Scholar
• GNANAPAVAN S, KOLA B, BUSTIN SA et al: The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. I Clin. Endocrinol Metab. (2002) 87:2988–2991.
   PubMed Web of Science ®Google Scholar
• NAKAZATO M, MURAKAMI N, DATE Y et al.: A role for ghrelin in the central regulation of feeding. Nature (2001) 409:194–198.
   PubMed Web of Science ®Google Scholar
• WREN AM, SMALL CJ, WARD HL et al.: The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology(2000) 41:4325–4328.
   Google Scholar
• WREN AM, SMALL CJ, ABBOTT CR et al.: Ghrelin causes hyperphagia and obesity in rats. Diabetes (2001) 50:2540–2547.
   PubMed Web of Science ®Google Scholar
• TSCHOP M, SMILEY DL, HEIMAN ML: Ghrelin induces adiposity in rodents. Nature (2000) 407:908–913.
   PubMed Web of Science ®Google Scholar
• ••First report on the adipogenic properties ofghrelin.
   Google Scholar
• DATE Y, NAKAZATO M, MURAKAMI N et al.: Ghrelin acts in the central nervous system to stimulate gastric acid secretion. Biochem. Biophys. Res. Commun. (2001) 280:904–907.
   PubMed Web of Science ®Google Scholar
• MASUDA Y, TANAKA T, INOMATA N et al.: Ghrelin stimulates gastric acid secretion and motility in rats. Biochem. Biophys. Res. Commun. (2000) 276: 905–908.
   PubMed Web of Science ®Google Scholar
• PEINO R, BALDELLI R, RODRIGUEZ-GARCIA J et al.: Ghrelin-induced growth hormone secretion in humans. Ear: Endocrinol (2000) 143:R11–R14.
   Web of Science ®Google Scholar
• WREN AM, SEAL LJ, COHEN MA et al.: Ghrelin enhances appetite and increases food intake in humans. I Clin. Endocrinol Metab. (2001) 86:5992–5995.
   PubMed Web of Science ®Google Scholar
• ARVAT E, MACCARIO M, DI VITO L et al: Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. j. Clin. Endocrinol Metab. (2001) 86:1169–1174.
   PubMed Web of Science ®Google Scholar
• HATAYA Y, AKAMIZU T, TAKAYA K et al.: A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans. j. Clin. Endocrinol Metab. (2001) 86:4552–4555.
   PubMed Web of Science ®Google Scholar
• BROGLIO F, ARVAT E, BENSO A et al: Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. I Clin. Endocrinol Metab. (2001) 86:5083–5086.
   PubMed Web of Science ®Google Scholar
• NAGAYA N, KOJIMA M, UEMATSU M et al.: Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am. Physiol (2001) 280:R1483–R1487.
   Web of Science ®Google Scholar
• KAMEGAI J, TAMURA H, SHIMIZU T et al.: Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and agouti-related protein mRNA levels and body weight in rats. Diabetes (2001) 50:2438–2443.
   PubMed Web of Science ®Google Scholar
• SHINTANI M, OGAWA Y, EBIHARA K et al.: Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes (2001) 50:227–232.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ MW, WOODS SC, PORTE Jr. D, SEELEY RJ, BASKIN DG: Central nervous system control of food intake. Nature (2000) 404:661–671.
   Google Scholar
• CUMMINGS DE, PURNELL JQ, FRAYO RS et al.: A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes (2001) 50:1714–1719.
   PubMed Web of Science ®Google Scholar
• TSCHOP M, WAWARTA R RIEPL RL et al.: Post-prandial decrease of circulating human ghrelin levels. I Endocrinol Invert. (2001) 24:RC19-RC21.
   Google Scholar
• ARIYASU H, TAKAYA K, TAGAMI T et al.: Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J. Clin. Endocrinol Metab. (2001) 86:4753–4758.
   PubMed Web of Science ®Google Scholar
• MULLER AF, LAMBERTS SW, JANSSEN JA et al.: Ghrelin drives GH secretion during fasting in man. Ear: Endocrinol (2002) 146:203–207.
   PubMed Web of Science ®Google Scholar
• OTTO B, CUNTZ U, FRUEHAUF E et al:Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur: I Endocrinol (2001) 145:R5–R9.
   Web of Science ®Google Scholar
• TSCHOP M, WEYER C, TATARANNI PA et al: Circulating ghrelin levels are decreased in human obesity. Diabetes (2001) 50:707–709.
   PubMed Web of Science ®Google Scholar
• CUMMINGS DE, WEIGLE DS, FRAYO RS et al.: Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N. Engl. I Med. (2002) 346:1623–1630.
   PubMed Web of Science ®Google Scholar
• ••First report linking low ghrelin levels inhuman subjects to reduced food intake.
   Google Scholar
• HANSEN TK, DALL R HOSODA H et al: Weight loss increases circulating levels of ghrelin in human obesity. Clin. Endocrinol (2002) 56:203–206.
   PubMed Web of Science ®Google Scholar
• JEFFERY PL, HERINGTON AC, CHOPIN LK: Expression and action of the growth hormone releasing peptide ghrelin and its receptor in prostate cancer cell lines. Endocrinol (2002) 172:R7–R11.
   Web of Science ®Google Scholar
• VOLANTE M, ALLIA E, GUGLIOTTA P et al.: Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. I Clin. Endocrinol Metab. (2002) 87:1300–1308.
   PubMed Web of Science ®Google Scholar
• PAPOTTI M, CASSONI P, VOLANTE M et al.: Ghrelin-producing endocrine tumors of the stomach and intestine. I Clin. Endocrinol Metab. (2001) 86:5052–5059.
   PubMed Web of Science ®Google Scholar
• JEFFERY PL, HERINGTON AC, CHOPIN LK: Expression and action of the growth hormone releasing peptide ghrelin and its receptor in prostate cancer cell lines. Endocrinol (2002) 172:R7–R11.
   Web of Science ®Google Scholar
• CASSONI P, PAPOTTI M, GHE C et al: Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. I Clin. Endocrinol. Metab. (2001) 86:1738–1745.
   PubMed Web of Science ®Google Scholar
• GHE C, CASSONI P, CATAPANO F et al: The antiproliferative effect of synthetic peptidyl GH secretagogues in human CALU-1 lung carcinoma cells. Endocrinology (2002) 143:484–491.
   PubMed Web of Science ®Google Scholar
• WANG G, LEE H-M, ENGLANDER E, GREELEY GH:Ghrelin-not just another stomach hormone. Regal. Pept. (2002) 105:75–81.
   PubMedGoogle Scholar
• ••Excellent summary of the physiologicalproperties of ghrelin.
   Google Scholar
• MUCCIOLI G, TSCHOP M, PAPOTTI M, DEGHENGHI R, HEIMAN M, GHIGO E: Neuroendocrine and peripheral activities of ghrelin:implications in metabolism and obesity. Eur.j. Pharmacol (2002) 440:235–254.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive review describing thepharmacology of ghrelin.
   Google Scholar
• HORVATH TL, DIANO S, SOTONYI P, HEIMAN M, TSCHOP M: Minireview: ghrelin and the regulation of energy balance-a hypothalamic perspective. Endocrinology (2001) 142:4163–4169.
   PubMed Web of Science ®Google Scholar
• •Detailed description of the hypothalamic circuitry involved in the regulation of energy homeostasis, with an emphasis on ghrelin.
   Google Scholar
• GIBNEY J, WALLACE JD, SPINKS T et at.: The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. I Clin. Endocrinol. Metab. (1999) 84:2596–2602.
   Google Scholar
• THORNER M, ROCHICCIOLI P, COLLE M et al.: Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient child during the first year of therapy. I Clin. Endocrinol. Metab. (1996) 81:1189–1196.
   PubMed Web of Science ®Google Scholar
• GENTH-ZOTZ S, ZOTZ R, GEIL S et al:Recombinant growth hormone therapy in patients with ischemic cardiomyopathy: effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity. Circulation (1999) 99:18–21.
   PubMed Web of Science ®Google Scholar
• SCHAMBELAN M, MULLIGAN K, GRUNFELD C et al.: Recombinant human growth hormone in patients with HIV-associated wasting; a randomized, placebo-controlled trial. Ann. Intern. Med. (1996) 125:873–882.
   PubMed Web of Science ®Google Scholar
• WOLF SE, NICOLAI M, DAGENAIS G: Growth hormone treatment in catabolic states other than burns. Growth Horm. IGF Res. (1998) 8:117–119.
   PubMedGoogle Scholar
• RUDMAN D, FELLER AG, NAGRAJ HS et al.: Effects of human growth hormone in men over 60 years old. N Engl. I Med. (1990) 323:1–6.
   PubMed Web of Science ®Google Scholar
• NAGAYA N, UEMATSU M, KOJIMA M et al: Elevated circulating level of ghrelin in cachexia associated with chronic heart failure. Relationships between ghrelin and anabolic/ catabolic factors. Circulation (2001) 104:2034–2038.
   Google Scholar
• WISSE BE, FRAYO RS, SCHWARTZ MW, CUMMINGS DE: Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology (2001) 142:3292–3301.
   PubMed Web of Science ®Google Scholar
• ASAKAWA A, INUI A, KAGA T et al.: Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology (2001) 120:337–345.
   PubMed Web of Science ®Google Scholar
• DEGHENGHI RCANANZI MM, TORSELLO A et al.: GH-releasing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sci. (1994) 54:1321–1328.
   PubMed Web of Science ®Google Scholar
• BOWERS CY: GH releasing peptides-structure and kinetics. Pediatr. Endocrinol (1993) 6:21–31.
   PubMed Web of Science ®Google Scholar
• RAUN K, HANSEN BS, JOHANSEN NL et al: Ipamorelin, the first selective growth hormone secretagogue. Ear. Endocrinol. (1998) 139:552–561.
   PubMed Web of Science ®Google Scholar
• ELIAS KA, INGLE GS, BURNIER JP et al: In vitro characterizations of four novel classes of growth hormone-releasing peptide. Endocrinology (1995) 12:5694–5699.
   Google Scholar
• HANSEN BS, RAUN K, NIELSEN KK et al: Pharmacological characterization of a new oral GH secretagogue, NN703. Ear. J. Endocrinol (1999) 141:180–189.
   PubMed Web of Science ®Google Scholar
• PATCHETT AA, NARGUND RP, TATA JR et al.: Design and biological activities of L-163,191 (MK-0677):a potent, orally active growth hormone secretagogue. Proc. Natl. Acad. Sci. (1995) 92:7001–7005.
   PubMed Web of Science ®Google Scholar
• •Report describing the first orally active peptidomirnetic GHS.
   Google Scholar
• PAN LC, CARPINO PA, LEFKER BA et al:Preclinical pharmacology of CP-424,391, an orally active pyrazolidinone-piperidine growth hormone secretagogue. Endocrine (2001) 14:121–132.
   PubMed Web of Science ®Google Scholar
• SMITH RG, CHENG K, SCHOEN WR et al.: A nonpeptidyl growth hormone secretagogue. Science (1993) 260:1640–1643.
   PubMed Web of Science ®Google Scholar
• DEAN DC, NARGUND RP, PONG S-S et al.: Development of a high specific activity sulfur-35-labeled sulfonamide radioligand that allowed the identification of a new growth hormone secretagogue receptor. J. Med. Chem. (1996) 39:1767–1770.
   PubMed Web of Science ®Google Scholar
• MUCCIOLI G, PAPOTTI M, LOCATELLI V, GHIGO E, DEGHENGHI R: Binding of 125I-labelled ghrelin to membranes from human hypothalamus and pituitary gland. J. Endocrinol. Invest (2001) 24:RC7-RC9.
   Google Scholar
• SMITH RG, VAN DER PLOEG LHT, HOWARD AD et al.: Peptidomimetic regulation of growth hormone secretion. Endocr. Rev (1997) 18:621–645.
   Google Scholar
• AHNFELT-RONNE I, NOWAK J, OLSEN UB: Do growth hormone-releasing peptides act as ghrelin secretagogues? Endocrine (2001) 14:133–135.
   PubMed Web of Science ®Google Scholar
• GHIGO E, ARVAT E, GIORDANO R et al.: Biologic activities of growth hormone secretagogues in humans. Endocrine (2001) 14:87–93.
   PubMed Web of Science ®Google Scholar
• BOWERS CY, REYNOLDS GA, DURHAM D, BARRERA CM, PEZZOLI SS, THORNER MO: Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. Clin. Endocrinol. Metab. (1990) 70:975–982.
   Google Scholar
• YANG L, MORRIELLO G, PATCHETT AA et al.:1- [2(R)- (2-Amino-2-methylpropionylamino)-3- (1H-indo1-3-yl)propionyll -3-benzylpiperidine-3(S)-carboxylic Acid Ethyl Ester (L-163,540):a potent, orally bioavailable, and short-duration growth hormone secretagogue. Med. Chem. (1998) 41:2439–2441.
   Web of Science ®Google Scholar
• JOHANSEN PB, NOWAK J, SKJAERBAEK C et al: Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm. IGF Res. (1999) 9:106–113.
   PubMed Web of Science ®Google Scholar
• SVENSSON J, LALL S, DICKSON SL et al.: The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J. Endocrinol (2000) 165:569–577.
   PubMed Web of Science ®Google Scholar
• CELLA SG, CERRI CG, DANIEL Set al.: Sixteen weeks of hexarelin therapy in aged dogs: effects on the somatotropic axis, muscle morphology, and bone metabolism. Gerontol A. Bio. Sci. Med. Sri. (1996) 51:B439–B447.
   Google Scholar
• ANDERSEN NB, MALMLOF K, JOHANSEN PB et al: The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm. IGF Res. (2001) 11:266–272.
   PubMedGoogle Scholar
• ISGAARD J, TIVESTEN A, FRIBERG P, BENGTSSON B-A:The role of the GH/ IGF-I axis for cardiac function and structure. Horm. Metab. Res. (1999) 31:50–54.
   PubMed Web of Science ®Google Scholar
• TIVESTEN A, BOLLANO E, CAIDAHL K et al.: The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. Endocrinology (2000) 141:60–66.
   PubMed Web of Science ®Google Scholar
• MACANDREW JT, ELLERY SS, PARRY MA, PAN LC, BLACK SC: Efficacy of a growth hormone-releasing peptide mimetic in cardiac ischemia/reperfusion injury. Eur. Pharmacol (2001) 432:195–202.
   PubMed Web of Science ®Google Scholar
• KING MK, GAY DM, PAN LC et al: Treatment with a growth hormone secretagogue in a model of developing heart failure. Effects on ventricular and myocyte function. Circulation (2001) 103:308–313.
   PubMed Web of Science ®Google Scholar
• TSCHOP M, STATNICK MA, SUTER TM, HEIMAN ML: GH-releasing peptide-2 increases fat mass in mice lacking NPY: indication for a crucial mediating role of hypothalamic agouti-related protein. Endocrinology (2002) 143:558–568.
   PubMed Web of Science ®Google Scholar
• LALL S, TUNG LYC, OHLSSON C, JANSSON J-0, DICKSON SL: Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem. Biophys. Res. Commun. (2001) 280:132–138.
   PubMed Web of Science ®Google Scholar
• LARON Z, FRENKEL J, DEGHENGHI R ANIN S, KLINGER B, SILBERGELD A: Intranasal administration of the GHRP hexarelin accelerates growth in short children. Clin. Endocrinol (1995) 43:631–635.
   PubMed Web of Science ®Google Scholar
• MERICQ V, CASSORLA F, SALAZAR T et al.: Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. Clin. Endocrinol Metab. (1998) 83:2355–2360.
   Google Scholar
• GHIGO E, ARVAT E, CAMANNI F: Orally active growth hormone secretagogues:state of the art and clinical perspectives. Ann. Med. (1998) 30:159–168.
   PubMed Web of Science ®Google Scholar
• CODNER E, CASSORLA F, TIULPAKOV AN et al.: Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children. Clin. Pharmacol The]: (2001) 70:91–98.
   PubMed Web of Science ®Google Scholar
• CHAPMAN IM, BACH MA, VAN CAUTER E et al: Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects../. Clin. Endocrinol Metab. (1996) 81:4249–4257.
   PubMed Web of Science ®Google Scholar
• BACH MA, CAMBRIA M: Growth hormone releasing peptides:growth studies. Carr. Opin. Endocrinol Diabetes(1999) 6:100–105.
   Google Scholar
• SVENSSON J, LONN L, JANSSON J-0 et al.: Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. I Clin. Endocrinol Metab. (1998) 83:362–369.
   Google Scholar
• MURPHY MG, BACH MA, PLOTKIN D et al.: Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults../. Bone Miner. Res. (1999) 14:1182–1188.
   Google Scholar
• PAPADAKIS MA, GRADY D, BLACK D et al.: Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann. Intern. Med. (1996) 124:708–716.
   PubMed Web of Science ®Google Scholar
• NARGUND RP, YE Z, TATA J et al: L-166,446, a second generation growth hormone secretagogue. 222' ACS National Meeting, Chicago, IL, USA (2001). MEDI–184.
   Google Scholar
• SMITH RG, SUN Y, SMITH AGA et al.: Ghrelin and a new class of synthetic GH secretagogues (GHS) activate the GHS receptor through a different site than GHRP-6 and MK-0677. 222" American Chemical Socieo, (ACS) National Meeting, Chicago, IL, USA (2001). MEDI–182.
   Google Scholar
• ANKERSEN M, NIELSEN KK, HANSEN TK et al.: Growth hormone secretagogues derived from NN703 with hydrazides at C-terminal. Ear: I Med. Chem. (2000) 35:487–497.
   Google Scholar
• ANDERSEN P, ANKERSEN M, JESSEN CU, LEHMAN SV: The synthesis of a GH-releasing compound NNC 26-1089. Org. Process Res. & Dev. (2002) 6:367–373.
   Web of Science ®Google Scholar
• HANSEN TK, ANKERSEN M, RAUN K, HANSEN BS: Highly potent growth hormone secretagogues:Hybrids of NN703 and ipamorelin. Bioorg. Med. Chem. Lett. (2001) 11:1915–1918.
   PubMed Web of Science ®Google Scholar
• JUNGHEIM LN: Imidazole-based growth hormone secretagogues: adventures encountered on the road to LY444711. 222" American Chemical Society (ACS) National Meeting, Chicago, IL, USA (2001). MEDI–183.
   Google Scholar
• SEYLER DE, DODGE JA, OSBORNE JJ et al.: Effect of growth hormone secretagogue LY444711 on IGF-1, growth hormone, and cortisol levels in beagle dogs after one and seven daily oral doses. Drug Dev. Res. (2000) 49:260–265.
   Web of Science ®Google Scholar
• YE Z, GAO Y, BAKSHI RK et al: Modeling directed design and biological evaluation of quinazolinones as non-peptidic growth hormone secretagogues. Bioorg. Med. Chem. Lett. (2000) 10:5–8.
   PubMed Web of Science ®Google Scholar
• HUANG P, LOEW GH, FUNAMIZU H et al.: Rational design, discovery, and synthesis of a novel series of potent growth hormone secretagogues. Med. Chem. (2001) 44:4082–4091.
   Web of Science ®Google Scholar
• ANKERSEN M, JOHANSEN NL, MADSEN K et al.: A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. I Med. Chem. (1998) 41:3699–3704.
   PubMed Web of Science ®Google Scholar
• NAGAMINE J, NAGATA R SEKI H et al.: Pharmacological profile of a new orally active growth hormone secretagogue, SM-130686. Endocrinol (2001) 171:481–489.
   Google Scholar
• •First report on the pharmacological characterisation of third generation GHSs.
   Google Scholar
• TOKUNAGA T, HUME WE, UMEZOME T et al: Oxindole derivatives as orally active potent growth hormone secretagogues. I Med. Chem. (2001) 44:4641–4649.
   PubMed Web of Science ®Google Scholar
• BEDNAREK MA, FEIGHNER SD, PONG S-S et al: Structure-function studies on the new growth hormone-releasing peptide, ghrelin:minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor la. I Med. Chem (2000) 43:4370–4376.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO M, HOSODA H, KITAJIMA Y et al.: Structure-activity relationship of ghrelin: pharmacological study of ghrelin peptides. Biochem. Biophys. Res. Commun. (2001) 287:142–146.
   PubMed Web of Science ®Google Scholar
• TORSELLO A, GHE C, BRESCIANI E et al.:Short ghrelin peptides neither displace ghrelin binding in vitro nor stimulate GH release M vivo. Endocrinology (2002) 143:1968–1971.
   PubMed Web of Science ®Google Scholar
• PALUCKI BL, FEIGHNER SD, PONG S-S et al: Spiro(indoline-3,4'-piperidine) growth hormone secretagogues as ghrelin mimetics. Bioorg. Med. Chem. Lett. (2001) 11:1955–1957.
   PubMed Web of Science ®Google Scholar
• SMITH RG, GRIFFIN PR, XU Y et al.: Adenosine: a partial agonist of the growth hormone secretagogue receptor. Biochem. Biophys. Res. Common (2000) 276:1306–1313.
   PubMed Web of Science ®Google Scholar
• TULLIN S, HANSEN BS, ANKERSEN M et al.: Adenosine is an agonist of the growth hormone secretagogue receptor. Endocrinology(2000) 141:3397–3402.
   PubMedGoogle Scholar
• CHENG K, WEI L, CHAUNG L-Y et aL: Inhibition of L-692,429-stimulated rat growth hormone release by a weak substance P antagonist:L-756,867. J Endocrinol (1997) 152:155–158.
   PubMed Web of Science ®Google Scholar
• CHENG K, CHAN WWS, BUTLER B, WEI L, SMITH RG: A novel non-peptidyl growth hormone secretagogue. Horm. Res. (1993) 40:109–115.
   PubMedGoogle Scholar
• SHUTO Y, SHIBASAKI T, OTAGIRI A et al.: Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity.' Clin. Invest. (2002) 109:1429–1436.
   Google Scholar
• ••Report describing site-specific GHS-Rla knockout in a transgenic rodent model.
   Google Scholar